Related Experiment Video
Updated: Jul 5, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Clinical analysis of 12 cases of uterine carcinosarcoma]
Luan-Hong Wang1, Ying Xiong, Yan-Fang Li
1State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.
Background & Objective:
Uterine carcinosarcoma, also known as malignant mixed mullerian tumors, is an uncommon neoplasm that carries a poor prognosis. This study was to analyze the clinical manifestation, diagnosis, treatment and prognosis of this disease.
Methods:
Clinical data of 12 uterine carcinosarcoma patients, diagnosed in Cancer Center of Sun Yat-sen University from 1978 to 2004, were analyzed.
Results:
Of the 12 cases of uterine carcinosarcoma, 2 were in the cervix, 10 in the corpus uteri. The main clinical manifestation of cervical carcinosarcoma was contact vaginal bleeding. Carcinosarcoma in the corpus uteri manifested abnormal vaginal bleeding and postmenstrual bleeding. Diagnosis depended on pathology. Twelve patients undergone operation. Eight patients received chemotherapy and 2 received radiotherapy after operation. One cervical carcinosarcoma patient died within 2 year. The 1-, 3-, and 5-year survival rates of the 12 patients were 80.0%, 50.0%, and 50.0%,respectively.
Conclusions:
Primary surgery is the main treatment for uterine carcinosarcoma. The prognosis of uterine carcinosarcoma is associated with surgicopathologic stage and treatment modalities.
